Rakovina Therapeutics Partners with St. Baldrick’s Foundation to Research and Develop New Treatments for Childhood Bone Cancer
VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), a biopharmaceutical company committed to advancing novel cancer therapies based on novel DNA damage response technologies, today announced that the company has been selected to participate in a US$975,000 (CDN1,297,000) three-year research program funded by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which aims to develop novel treatments for Ewing’s sarcoma, an aggressive bone and soft tissue cancer in children and young adults. adults.
Prof. dr. Mads Daugaard, President of Rakovina Therapeutics and Chief Scientific Officer, is a principal investigator on the project, along with Prof. Paul Sorensen at the University of British Columbia. Rakovina Therapeutics recently presented preclinical data at peer-reviewed scientific meetings demonstrating the potential of Rakovina Therapeutics’ kt-3000 series drug candidates against treatment-resistant cancer cell lines, including Ewing’s sarcoma.
“Our data demonstrate that kt-3000 series compounds are equivalent or more effective against Ewing sarcoma cells in vitro compared to FDA-approved PARP inhibitors, which are used as benchmarks of activity, said Prof. Daugaard.” there are no FDA-approved treatments for recurrent Ewing sarcoma, which is largely resistant to conventional therapies and immunotherapy; new treatment strategies are desperately needed.”
Rakovina Therapeutics will provide test compounds and support the project with technical personnel. Funding from the St. Baldrick’s Foundation will support preclinical IND-supportive research conducted at the University of British Columbia over the next 12 months.
Martha’s Better Ewing Sarcoma Treatment (BEST) Grant for all is named a St. Baldrick’s scholarship in honor of a 19-year-old girl who has battled the disease for more than 6 years, after being first diagnosed with Ewing’s sarcoma in 2015 at age 13. Martha was happy to have her name associated with the grant, but insisted on the “for everyone” to acknowledge the many other children diagnosed with Ewing sarcoma each year. Having faced numerous relapses over the years, Martha is fearless and continues her battle with Ewing’s sarcoma. Martha continues to place her trust in the cancer research community and plans to enroll in a clinical trial at Boston Children’s Hospital in December 2021.
“This incredibly generous gift enabled us to partner with the University of British Columbia to seek and fund new research into Ewing sarcoma,” said Kathleen Ruddy, chief executive officer of St. Baldrick’s Foundation. “Recently reported data from Rakovina Therapeutics shows early promise as a potential treatment for Ewing sarcoma and we are pleased to welcome the company to this important project, which supports groundbreaking research in the hope of finding new treatments for this deadly disease.”
“Thousands of donors and volunteers have made the St. Baldrick’s Foundation the largest non-governmental funder of childhood cancer research grants. Our volunteers and scientists work tirelessly to ensure that current and future children diagnosed with cancer have access to the best treatments and that tomorrow’s treatments will have fewer long-term toxic effects,” said Ms Ruddy.
“Rakovina Therapeutics is pleased to be an industry partner in the St. Baldrick’s Foundation’s mission to support the most promising research to find treatments for childhood cancer and help survivors live long, healthy lives,” said Jeffrey Bacha, executive chairman of Rakovina Therapeutics. “We will strive to bring drug candidates quickly to the clinical arena if preclinical IND work permits.”
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. focuses on the development of new cancer treatments based on novel DNA damage response technologies. The company has established a pipeline of DNA damage response inhibitors with the goal of bringing one or more drug candidates into human clinical trials and gaining marketing approval for novel cancer therapies from Health Canada, the U.S. Food and Drug Administration. Administration and Similar International Regulatory Bodies. More information can be found at www.rakovinatherapeutics.com.
The TSXV has not approved or disapproved of the contents of this press release. Neither the TSXV nor its Regulatory Services Provider (as that term is defined in the TSXV’s policies) assumes any responsibility for the suitability or accuracy of this release.
Notice Regarding Forward-Looking Statements:
This press release contains forward-looking statements regarding the company and its respective activities, which may include, but are not limited to, statements regarding the company’s proposed business plan and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “expects,” “expects,” “planned,” “intends,” “considers,” “anticipates,” “believes” , “proposes” or variations (including negative variations) of such words and expressions, or states that certain actions, events or results “may”, “could”, “should”, “should” or “will” be taken, occur or are achieved. Such statements are based on the Company’s management’s current expectations. The forward-looking events and conditions discussed in this press release may not occur on certain specified dates or at all and could differ materially due to known and unknown risk factors and uncertainties affecting the Company, including risks related to the medical device industry, economic factors, regulatory factors, the stock markets in general and risks related to growth and competition. While the company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that could cause actions, events or results to differ from those expected, estimated or meant. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date they are made and the Company assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com.